(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

FORMAS CRISTALINAS E POLIMORFOS DE DERIVADO DE TIOFENO, COMPOSIÇÃO FARMACÊUTICA QUE OS COMPREENDE, SEU PROCESSO DE PREPARAÇÃO, SEU USO E MÉTODOS DE TRATAMENTO DE DOENÇA ASSOCIADA A ENZIMA PDE4 E DE REDUÇÃO DA ATIVIDADE DE PD4

Em ExigênciaInvention PatentPCT · CN2019085360

Application data

Number

112020021945

Type

Invention Patent

Filing

04/30/2019

Publication

01/26/2021

PCT

CN2019085360

Progress at the INPI

Office action pending
  1. Filing04/30/19
  2. Publication01/26/21
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical office action on this application. If it is not answered in time, the application is abandoned (art. 36 of the Brazilian IP Act).

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 09/19/2023. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

TIANJIN HEMAY PHARMACEUTICAL CO., LTD.

CN

Inventors

D. Z. (pessoa física)

CN

L. W. (pessoa física)

CN

X. L. (pessoa física)

CN

Technical data

Priority claims

CN

201810407741.X · 05/02/2018

Abstract

FORMAS CRISTALINAS DE DERIVADOS DE TIOFENO.São descritos um polimorfo, a forma cristalina III e a forma cristalina IV do composto (S)-N-[5-[1-(3-etóxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4H-tieno[3,4-c]pirrol-1-il]acetamida.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

6.7

Vide Parecer

09/19/2023

RPI 2750

6.7

Vide Paracer

06/27/2023

RPI 2738

Parecer de pré-exame

#6.23

03/28/2023

RPI 2725

Adição na publicação

#15.35

12/14/2021

RPI 2658

Notificação de entrada na fase nacional - PCT

#1.3

01/26/2021

RPI 2612

Alteração de dados cadastrais

#1.1

11/10/2020

RPI 2601

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.